Seven analysts cut target for Nanosonics stock to AUD 3.88

Published on 10/20/2026 at 19:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nanosonics posted AUD 203.90 million revenue in fiscal 2026, up 2.70 percent. Nanosonics stock costs EUR 1.88 on October 20, 2026 at 7:43 p.m. CEST.

Analyst target and reporting date

Seven analysts lowered the average target to AUD 3.88 from AUD 4.23 on September 25, 2026.
Fiscal 2026 revenue reached AUD 203.90 million, up 2.70 percent year over year.
Nanosonics stock costs EUR 1.88 at Lang & Schwarz on October 20, 2026 at 7:43 p.m. CEST.
The annual meeting is scheduled for November 4, 2026.

Nanosonics, AU000000NAN9, Illustration mit AI erstellt.

Seven analysts lowered the average target for Nanosonics from AUD 4.23 to AUD 3.88 on September 25, 2026, according to Simply Wall St. The new target was 29.33 percent above the ASX price of AUD 3.00 at 3:10 p.m. AEDT on October 20, 2026. At Lang & Schwarz, Nanosonics was trading at EUR 1.88 on October 20, 2026 at 7:43 p.m. CEST.

Revenue growth stays measured

Nanosonics reported fiscal 2026 revenue of AUD 203.90 million, a 2.70 percent increase from fiscal 2025, while net income reached AUD 17.84 million. Kapitales Research reported that earnings before interest and tax fell 10.00 percent to AUD 16.00 million in fiscal 2026 as currency movements and expansion spending weighed on the result.

Stock remains below its yearly high

The ASX price of AUD 3.00 on October 20, 2026 stood within a 52-week range of AUD 2.64 to AUD 4.76. The same quote showed a market capitalization of AUD 897.5 million, a price-to-earnings ratio of 51.99 and volume of 828,224 shares. The stock was 36.97 percent below its 52-week high, calculated from AUD 3.00 and AUD 4.76.

Valuation meets a November date

The scheduled annual meeting on November 4, 2026 gives shareholders the next dated company event. Simply Wall St lists the meeting date and the Macquarie Park location. The company operates in infection prevention and sells trophon ultrasound probe disinfection systems, while CORIS is being prepared for commercial rollout in fiscal 2027.

Comparison with peers

Pro Medicus (ASX, AUD): up 1.29 percent, price-to-earnings ratio 70.84, market capitalization AUD 18.8 billion on October 20, 2026 at 3:10 p.m. AEDT. Fisher & Paykel Healthcare (ASX, AUD): up 0.50 percent, price-to-earnings ratio 62.14, market capitalization AUD 23.5 billion on October 20, 2026 at 3:10 p.m. AEDT.

Target and trading level

The analyst average of AUD 3.88 remains above Nanosonics' ASX price of AUD 3.00, but the fiscal 2026 revenue increase was accompanied by lower reported earnings before interest and tax. That combination leaves the November meeting and CORIS rollout as the next dated points for assessing execution.

The stock stood at EUR 1.88 at Lang & Schwarz on October 20, 2026 at 7:43 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Nanosonics stock.